Scholarlink

<p>Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterised by impaired insulin signalling, chronic hyperglycaemia, and associated metabolic dysfunction. Plant-derived bioactive compounds are increasingly explored as potential therapeutic agents for its management. To investigate the anti-diabetic effect and underlying mechanism of Myrcene, in streptozotocin (STZ) + high-fat diet (HFD) induced diabetes in mice, male C57BL/6 mice were administered HFD for eight consecutive weeks, followed by low-dose STZ injections (60&#xa0;mg/kg) during the succeeding week to develop diabetes. After diabetes was established, the mice received a daily oral dose of Myrcene (50&#xa0;mg/kg) for 15 days. The research evaluated changes in physiological parameters, blood biomarkers (such as glucose, lipoprotein, etc.), and tissue structure. Furthermore, molecular docking and western blot analyses were performed to examine the expression of oxidative stress markers regulated by the Nrf2 pathway in diabetic pancreatic tissue from mice. We found that Myrcene restored insulin levels by ~ 4-fold (4.01 ± 0.32) with reference to diabetic control, along with body weight, and reduced blood glucose levels by ~ 0.5-fold (11.53 ± 1.62). The administration of Myrcene increased high-density lipoprotein (HDL) (46.77 ± 3.90) and decreased many lipid profile markers compared with diabetic control, suggesting its hypolipidemic action. Later, docking results indicated that myrcene exhibits a higher binding affinity for Nrf2 than for other molecular targets, and western blot data showed that myrcene enhanced Nrf2 protein production. Myrcene exhibited antidiabetic, hypolipidemic, and antioxidative properties in HFD-STZ-induced diabetic mice, supporting its potential use as an antidiabetic supplement.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

NRF2 activation by myrcene restores redox balance and metabolic homeostasis in a mouse model of type 2 diabetes

  • 期刊论文

  • 发表日期：

    2026年5月25日

查看全文
  • Ruchi Pandey,
  • Adarsh Kumar Ray,
  • Priya Bisht,
  • Shalini Choudhary,
  • Prabhat Kumar,
  • Anita Kumari,
  • Nitesh Kumar

摘要

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterised by impaired insulin signalling, chronic hyperglycaemia, and associated metabolic dysfunction. Plant-derived bioactive compounds are increasingly explored as potential therapeutic agents for its management. To investigate the anti-diabetic effect and underlying mechanism of Myrcene, in streptozotocin (STZ) + high-fat diet (HFD) induced diabetes in mice, male C57BL/6 mice were administered HFD for eight consecutive weeks, followed by low-dose STZ injections (60 mg/kg) during the succeeding week to develop diabetes. After diabetes was established, the mice received a daily oral dose of Myrcene (50 mg/kg) for 15 days. The research evaluated changes in physiological parameters, blood biomarkers (such as glucose, lipoprotein, etc.), and tissue structure. Furthermore, molecular docking and western blot analyses were performed to examine the expression of oxidative stress markers regulated by the Nrf2 pathway in diabetic pancreatic tissue from mice. We found that Myrcene restored insulin levels by ~ 4-fold (4.01 ± 0.32) with reference to diabetic control, along with body weight, and reduced blood glucose levels by ~ 0.5-fold (11.53 ± 1.62). The administration of Myrcene increased high-density lipoprotein (HDL) (46.77 ± 3.90) and decreased many lipid profile markers compared with diabetic control, suggesting its hypolipidemic action. Later, docking results indicated that myrcene exhibits a higher binding affinity for Nrf2 than for other molecular targets, and western blot data showed that myrcene enhanced Nrf2 protein production. Myrcene exhibited antidiabetic, hypolipidemic, and antioxidative properties in HFD-STZ-induced diabetic mice, supporting its potential use as an antidiabetic supplement.